under our collaboration with celgene , we are developing small molecule inhibitors directed to three other hmt targets , in addition to 76 pinometostat . we are responsible for all preclinical discovery work as well as phase 1 clinical development for all three targets . celgene has the option to license worldwide rights to inhibitors directed at two of the three targets , and the option to license ex-u.s. rights to inhibitors directed to the third target . we retain the rights to develop and commercialize inhibitors of the third target in the united states . beyond our two clinical stage programs and the partnered programs with gsk and celgene , we have also identified five novel epigenetic targets for which we are developing small molecule inhibitors in preclinical drug discovery . we own the global development and commercialization rights to these programs . all of our novel targets have been identified internally using our proprietary drug discovery platform , and all of our small molecule inhibitors have been discovered internally . we commenced active operations in early 2008 , and since inception , have incurred significant operating losses . as of december 31 , 2015 , our accumulated deficit totaled $ 243.5 million . as a clinical stage company , we expect to continue to incur significant expenses and operating losses over the next several years . our net losses may fluctuate significantly from quarter to quarter and year to year . we expect our expenses to increase in connection with our ongoing activities , including as we execute on the following clinical development plans for tazemetostat : continue to enroll adult patients into all arms of our ongoing international , registration-supporting five-arm phase 2 study in up to 150 patients with nhl , present interim data from the study at a medical conference in mid-2016 and present a second interim analysis at a medical conference in late 2016 ; continue to enroll adult patients into all arms of our ongoing international , registration-supporting phase 2 three-arm study in up to 90 patients with certain genetically-defined solid tumors , and present interim data from the study at a medical conference in late 2016 ; continue to enroll pediatric patients into our ongoing international phase 1 dose escalation and dose expansion study in approximately 40 patients with certain genetically-defined solid tumors ; present data from the food effect and drug-drug interaction clinical pharmacology sub-studies of the ongoing phase 1 study in relapsed or refractory nhl or advanced solid tumors at a medical conference in the first half of 2016 and present final data from the phase 1 study in the second half of 2016 ; initiate a phase 1b/2 study in combination with r-chop in front line elderly patients with dlbcl in the first half of 2016 ; enter into an arrangement with a collaboration partner for a phase 1b study in combination with either an anti-pd1 antibody or an anti-pdl1 antibody in patients with relapsed or refractory dlbcl in the second quarter of 2016 and initiate this study in mid-2016 ; and initiate a phase 2 study in relapsed or refractory patients with mesothelioma characterized by bap1 loss-of-function by the third quarter of 2016. since our inception and through december 31 , 2015 , we have raised an aggregate of $ 592.1 million to fund our operations , of which $ 201.6 million was non-equity funding through our collaboration agreements , $ 314.5 million was from the sale of common stock in our public offerings and $ 76.0 million was from the sale of redeemable convertible preferred stock . as of december 31 , 2015 , we had $ 208.3 million in cash and cash equivalents . in addition , in january 2016 , we raised an additional $ 130.1 million of net proceeds after underwriting discounts and commissions , but before direct and incremental costs of the offering , upon the sale of 15.3 million shares of our common stock in a public offering . collaborations refer to item . 1 , collaborations and note 9 , collaborations , of the notes to our consolidated financial statements in item 15 of this annual report on form 10-k for a description of the key terms of our arrangements with eisai , celgene and gsk , as well as the related accounting and revenue recognition considerations . 77 results of operations for the years ended december 31 , 2015 , 2014 and 2013 collaboration revenue the following is a comparison of collaboration revenue for the years ended december 31 , 2015 , 2014 and 2013 : replace_table_token_4_th our revenue consists of collaboration revenue , including amounts recognized from deferred revenue related to upfront payments for licenses or options to obtain licenses in the future , research and development services revenue earned and milestone payments earned under collaboration and license agreements with our collaboration partners . the following table summarizes our collaboration revenue , by partner , for the years ended december 31 , 2015 , 2014 and 2013 : replace_table_token_5_th collaboration revenues for the year ended december 31 , 2015 decreased $ 38.8 million as compared to the year ended december 31 , 2014 , primarily as a result of the completion of a significant portion of our performance obligations under our collaborations during 2014 and achievement of a $ 3.0 million milestone under our agreement with gsk during 2014. collaboration revenue decreased $ 27.1 million in the year ended december 31 , 2014 as compared to 2013 , primarily as a result of $ 35.0 million of milestone payments recognized in 2013 related to the celgene , gsk and eisai collaborations , partially offset by higher research revenues associated with the gsk agreement in 2014. in 2013 , we recognized milestone revenue of $ 25.0 million from celgene related to achieving a proof of concept milestone for pinometostat , $ 4.0 million for achievement of two preclinical milestones with gsk and $ 6.0 million from eisai for achieving a story_separator_special_tag in those circumstances where we apply our best estimate of selling price to determine the estimated selling price of a license to our proprietary technology , we consider market conditions as well as entity-specific factors , including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity , estimated development costs , probability of success and the time needed to commercialize a product candidate pursuant to the license . in validating our best estimate of selling price , we evaluate whether changes in the key assumptions used to determine our best estimate of selling price will have a significant effect on the allocation of arrangement consideration between deliverables . we recognize consideration allocated to an individual element when all other revenue recognition criteria are met for that element . our multiple-element revenue arrangements generally include the following : exclusive licenses . the deliverables under our collaboration agreements generally include exclusive licenses to discover , develop , manufacture and commercialize compounds with respect to one or more specified hmt targets . to account for this element of the arrangement , we evaluate whether the exclusive license has standalone value from the undelivered elements to the collaboration partner based on the consideration of the relevant facts and circumstances of each arrangement , including the research and development capabilities of the collaboration partner and other market participants . arrangement consideration allocated to licenses may be recognized upon delivery of the license if facts and circumstances indicate that the license has standalone value apart from the undelivered elements , which generally include research and development services . arrangement consideration allocated to licenses is deferred if facts and circumstances indicate that the delivered license does not have standalone value from the undelivered elements . 85 we have determined that some of our exclusive licenses lack standalone value apart from the related research and development services , and in those circumstances we recognize collaboration revenue from non-refundable exclusive license fees on a straight-line basis over the contracted or estimated period of performance , which is generally the period over which the research and development services are to be provided . research and development services . the deliverables under our collaboration and license agreements generally include deliverables related to research and development services to be performed on behalf of the collaboration partner . as the provision of research and development services is a part of our central operations , when we are principally responsible for the performance of these services under the agreements , we recognize revenue on a gross basis for research and development services as those services are performed . option arrangements . our arrangements may provide a collaborator with the right to select a target for licensing either at the inception of the arrangement or within an initial pre-defined selection period , which may , in certain cases , include the right of the collaborator to extend the selection period . under these agreements , fees may be due to us at the inception of the arrangement as an upfront fee or payment , upon the exercise of an option to acquire a license or upon extending the selection period as an extension fee or payment . the accounting for option arrangements is dependent on the nature of the options granted to the collaboration partner . options are considered substantive if , at the inception of the arrangement , we are at risk as to whether the collaboration partner will choose to exercise the options to secure exclusive licenses . factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement , the benefit the collaborator might obtain from the arrangement without exercising the options , the cost to exercise the options relative to the total upfront consideration and the additional financial commitments or economic penalties imposed on the collaborator as a result of exercising the options . for arrangements under which the option to secure licenses is considered substantive , we do not consider the licenses to be deliverables at the inception of the arrangement . for arrangements where the option to secure licenses is not considered substantive , we consider the license to be a deliverable at the inception of the arrangement and , upon delivery of the license , would apply the multiple-element revenue arrangement criteria to the license and any other deliverables to determine the appropriate revenue recognition . none of the options to secure exclusive licenses included in our collaborative arrangements have been determined to be substantive . milestone revenue . our collaboration and license agreements generally include contingent milestone payments related to specified preclinical research and development milestones , clinical development milestones , regulatory milestones and sales-based milestones . preclinical research and development milestones are typically payable upon the selection of a compound candidate for the next stage of research and development . clinical development milestones are typically payable when a product candidate initiates or advances in clinical trial phases or achieves defined clinical events , such as proof-of-concept . regulatory milestones are typically payable upon submission for marketing approval with regulatory authorities , upon receipt of actual marketing approvals for a compound or for additional indications or upon the first commercial sale . sales-based milestones are typically payable when annual sales reach specified levels . at the inception of each arrangement that includes milestone payments , we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone . this evaluation includes an assessment of whether : the consideration is commensurate with either the entity 's performance to achieve the milestone or the enhancement of the value of the delivered item ( s ) as a result of a specific outcome resulting from the entity 's performance to achieve the milestone ; the consideration relates solely to past performance ; and 86 the consideration is reasonable relative to all

liquidity and capital resources through december 31 , 2015 , we have raised an aggregate of $ 592.1 million to fund our operations , of which $ 201.6 million was non-equity funding through our collaboration agreements , $ 314.5 million was from the sale of common stock in our public offerings and $ 76.0 million was from the sale of redeemable convertible preferred stock . as of december 31 , 2015 , we had $ 208.3 million in cash and cash equivalents . in addition , in january 2016 , we raised an additional $ 130.1 million of net proceeds after underwriting discounts and commissions , but before direct and incremental costs of the offering , upon the sale of 15,333,334 shares of our common stock in a public offering . as this event occurred in fiscal 2016 , it is not reflected in our december 31 , 2015 cash and cash equivalent balances . in addition to our existing cash and cash equivalents , we may receive research and development co-funding and are eligible to earn a significant amount of license and milestone payments under our collaboration agreements . our ability to earn these payments and the timing of earning these payments is dependent upon the outcome of our research and development activities and is uncertain at this time . funding requirements our primary uses of capital are , and we expect will continue to be , clinical trial costs , third party research and development services , compensation and related expenses , laboratory and related supplies , our potential future milestone payment obligations to eisai and roche under the amended eisai collaboration agreement and roche companion diagnostic agreement , legal and other regulatory expenses and general overhead costs . because our product candidates are in various stages of clinical and preclinical development and the outcome of these efforts is uncertain , we can not estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether , or when , we may achieve profitability .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources through december 31 , 2015 , we have raised an aggregate of $ 592.1 million to fund our operations , of which $ 201.6 million was non-equity funding through our collaboration agreements , $ 314.5 million was from the sale of common stock in our public offerings and $ 76.0 million was from the sale of redeemable convertible preferred stock . as of december 31 , 2015 , we had $ 208.3 million in cash and cash equivalents . in addition , in january 2016 , we raised an additional $ 130.1 million of net proceeds after underwriting discounts and commissions , but before direct and incremental costs of the offering , upon the sale of 15,333,334 shares of our common stock in a public offering . as this event occurred in fiscal 2016 , it is not reflected in our december 31 , 2015 cash and cash equivalent balances . in addition to our existing cash and cash equivalents , we may receive research and development co-funding and are eligible to earn a significant amount of license and milestone payments under our collaboration agreements . our ability to earn these payments and the timing of earning these payments is dependent upon the outcome of our research and development activities and is uncertain at this time . funding requirements our primary uses of capital are , and we expect will continue to be , clinical trial costs , third party research and development services , compensation and related expenses , laboratory and related supplies , our potential future milestone payment obligations to eisai and roche under the amended eisai collaboration agreement and roche companion diagnostic agreement , legal and other regulatory expenses and general overhead costs . because our product candidates are in various stages of clinical and preclinical development and the outcome of these efforts is uncertain , we can not estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether , or when , we may achieve profitability .
```    
 Suspicious Activity Report : under our collaboration with celgene , we are developing small molecule inhibitors directed to three other hmt targets , in addition to 76 pinometostat . we are responsible for all preclinical discovery work as well as phase 1 clinical development for all three targets . celgene has the option to license worldwide rights to inhibitors directed at two of the three targets , and the option to license ex-u.s. rights to inhibitors directed to the third target . we retain the rights to develop and commercialize inhibitors of the third target in the united states . beyond our two clinical stage programs and the partnered programs with gsk and celgene , we have also identified five novel epigenetic targets for which we are developing small molecule inhibitors in preclinical drug discovery . we own the global development and commercialization rights to these programs . all of our novel targets have been identified internally using our proprietary drug discovery platform , and all of our small molecule inhibitors have been discovered internally . we commenced active operations in early 2008 , and since inception , have incurred significant operating losses . as of december 31 , 2015 , our accumulated deficit totaled $ 243.5 million . as a clinical stage company , we expect to continue to incur significant expenses and operating losses over the next several years . our net losses may fluctuate significantly from quarter to quarter and year to year . we expect our expenses to increase in connection with our ongoing activities , including as we execute on the following clinical development plans for tazemetostat : continue to enroll adult patients into all arms of our ongoing international , registration-supporting five-arm phase 2 study in up to 150 patients with nhl , present interim data from the study at a medical conference in mid-2016 and present a second interim analysis at a medical conference in late 2016 ; continue to enroll adult patients into all arms of our ongoing international , registration-supporting phase 2 three-arm study in up to 90 patients with certain genetically-defined solid tumors , and present interim data from the study at a medical conference in late 2016 ; continue to enroll pediatric patients into our ongoing international phase 1 dose escalation and dose expansion study in approximately 40 patients with certain genetically-defined solid tumors ; present data from the food effect and drug-drug interaction clinical pharmacology sub-studies of the ongoing phase 1 study in relapsed or refractory nhl or advanced solid tumors at a medical conference in the first half of 2016 and present final data from the phase 1 study in the second half of 2016 ; initiate a phase 1b/2 study in combination with r-chop in front line elderly patients with dlbcl in the first half of 2016 ; enter into an arrangement with a collaboration partner for a phase 1b study in combination with either an anti-pd1 antibody or an anti-pdl1 antibody in patients with relapsed or refractory dlbcl in the second quarter of 2016 and initiate this study in mid-2016 ; and initiate a phase 2 study in relapsed or refractory patients with mesothelioma characterized by bap1 loss-of-function by the third quarter of 2016. since our inception and through december 31 , 2015 , we have raised an aggregate of $ 592.1 million to fund our operations , of which $ 201.6 million was non-equity funding through our collaboration agreements , $ 314.5 million was from the sale of common stock in our public offerings and $ 76.0 million was from the sale of redeemable convertible preferred stock . as of december 31 , 2015 , we had $ 208.3 million in cash and cash equivalents . in addition , in january 2016 , we raised an additional $ 130.1 million of net proceeds after underwriting discounts and commissions , but before direct and incremental costs of the offering , upon the sale of 15.3 million shares of our common stock in a public offering . collaborations refer to item . 1 , collaborations and note 9 , collaborations , of the notes to our consolidated financial statements in item 15 of this annual report on form 10-k for a description of the key terms of our arrangements with eisai , celgene and gsk , as well as the related accounting and revenue recognition considerations . 77 results of operations for the years ended december 31 , 2015 , 2014 and 2013 collaboration revenue the following is a comparison of collaboration revenue for the years ended december 31 , 2015 , 2014 and 2013 : replace_table_token_4_th our revenue consists of collaboration revenue , including amounts recognized from deferred revenue related to upfront payments for licenses or options to obtain licenses in the future , research and development services revenue earned and milestone payments earned under collaboration and license agreements with our collaboration partners . the following table summarizes our collaboration revenue , by partner , for the years ended december 31 , 2015 , 2014 and 2013 : replace_table_token_5_th collaboration revenues for the year ended december 31 , 2015 decreased $ 38.8 million as compared to the year ended december 31 , 2014 , primarily as a result of the completion of a significant portion of our performance obligations under our collaborations during 2014 and achievement of a $ 3.0 million milestone under our agreement with gsk during 2014. collaboration revenue decreased $ 27.1 million in the year ended december 31 , 2014 as compared to 2013 , primarily as a result of $ 35.0 million of milestone payments recognized in 2013 related to the celgene , gsk and eisai collaborations , partially offset by higher research revenues associated with the gsk agreement in 2014. in 2013 , we recognized milestone revenue of $ 25.0 million from celgene related to achieving a proof of concept milestone for pinometostat , $ 4.0 million for achievement of two preclinical milestones with gsk and $ 6.0 million from eisai for achieving a story_separator_special_tag in those circumstances where we apply our best estimate of selling price to determine the estimated selling price of a license to our proprietary technology , we consider market conditions as well as entity-specific factors , including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity , estimated development costs , probability of success and the time needed to commercialize a product candidate pursuant to the license . in validating our best estimate of selling price , we evaluate whether changes in the key assumptions used to determine our best estimate of selling price will have a significant effect on the allocation of arrangement consideration between deliverables . we recognize consideration allocated to an individual element when all other revenue recognition criteria are met for that element . our multiple-element revenue arrangements generally include the following : exclusive licenses . the deliverables under our collaboration agreements generally include exclusive licenses to discover , develop , manufacture and commercialize compounds with respect to one or more specified hmt targets . to account for this element of the arrangement , we evaluate whether the exclusive license has standalone value from the undelivered elements to the collaboration partner based on the consideration of the relevant facts and circumstances of each arrangement , including the research and development capabilities of the collaboration partner and other market participants . arrangement consideration allocated to licenses may be recognized upon delivery of the license if facts and circumstances indicate that the license has standalone value apart from the undelivered elements , which generally include research and development services . arrangement consideration allocated to licenses is deferred if facts and circumstances indicate that the delivered license does not have standalone value from the undelivered elements . 85 we have determined that some of our exclusive licenses lack standalone value apart from the related research and development services , and in those circumstances we recognize collaboration revenue from non-refundable exclusive license fees on a straight-line basis over the contracted or estimated period of performance , which is generally the period over which the research and development services are to be provided . research and development services . the deliverables under our collaboration and license agreements generally include deliverables related to research and development services to be performed on behalf of the collaboration partner . as the provision of research and development services is a part of our central operations , when we are principally responsible for the performance of these services under the agreements , we recognize revenue on a gross basis for research and development services as those services are performed . option arrangements . our arrangements may provide a collaborator with the right to select a target for licensing either at the inception of the arrangement or within an initial pre-defined selection period , which may , in certain cases , include the right of the collaborator to extend the selection period . under these agreements , fees may be due to us at the inception of the arrangement as an upfront fee or payment , upon the exercise of an option to acquire a license or upon extending the selection period as an extension fee or payment . the accounting for option arrangements is dependent on the nature of the options granted to the collaboration partner . options are considered substantive if , at the inception of the arrangement , we are at risk as to whether the collaboration partner will choose to exercise the options to secure exclusive licenses . factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement , the benefit the collaborator might obtain from the arrangement without exercising the options , the cost to exercise the options relative to the total upfront consideration and the additional financial commitments or economic penalties imposed on the collaborator as a result of exercising the options . for arrangements under which the option to secure licenses is considered substantive , we do not consider the licenses to be deliverables at the inception of the arrangement . for arrangements where the option to secure licenses is not considered substantive , we consider the license to be a deliverable at the inception of the arrangement and , upon delivery of the license , would apply the multiple-element revenue arrangement criteria to the license and any other deliverables to determine the appropriate revenue recognition . none of the options to secure exclusive licenses included in our collaborative arrangements have been determined to be substantive . milestone revenue . our collaboration and license agreements generally include contingent milestone payments related to specified preclinical research and development milestones , clinical development milestones , regulatory milestones and sales-based milestones . preclinical research and development milestones are typically payable upon the selection of a compound candidate for the next stage of research and development . clinical development milestones are typically payable when a product candidate initiates or advances in clinical trial phases or achieves defined clinical events , such as proof-of-concept . regulatory milestones are typically payable upon submission for marketing approval with regulatory authorities , upon receipt of actual marketing approvals for a compound or for additional indications or upon the first commercial sale . sales-based milestones are typically payable when annual sales reach specified levels . at the inception of each arrangement that includes milestone payments , we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone . this evaluation includes an assessment of whether : the consideration is commensurate with either the entity 's performance to achieve the milestone or the enhancement of the value of the delivered item ( s ) as a result of a specific outcome resulting from the entity 's performance to achieve the milestone ; the consideration relates solely to past performance ; and 86 the consideration is reasonable relative to all

